Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis

Summary: Background: Testosterone is the standard treatment for male hypogonadism, but there is uncertainty about its cardiovascular safety due to inconsistent findings. We aimed to provide the most extensive individual participant dataset (IPD) of testosterone trials available, to analyse subtypes...

Full description

Bibliographic Details
Main Authors: Jemma Hudson, MSc, Moira Cruickshank, PhD, Richard Quinton, MD, Lorna Aucott, PhD, Magaly Aceves-Martins, PhD, Katie Gillies, PhD, Shalender Bhasin, ProfMB BS, Peter J Snyder, ProfMD, Susan S Ellenberg, ProfPhD, Mathis Grossmann, ProfPhD, Thomas G Travison, PhD, Emily J Gianatti, PhD, Yvonne T van der Schouw, ProfPhD, Marielle H Emmelot-Vonk, ProfPhD, Erik J Giltay, PhD, Geoff Hackett, FRCPI, Sudarshan Ramachandran, PhD, Johan Svartberg, ProfPhD, Kerry L Hildreth, MD, Kristina Groti Antonic, PhD, Gerald B Brock, ProfMD, J Lisa Tenover, ProfMD, Hui Meng Tan, FRCS, Christopher Ho Chee Kong, FRCS, Wei Shen Tan, PhD, Leonard S Marks, ProfMD, Richard J Ross, ProfMD, Robert S Schwartz, ProfMD, Paul Manson, BA Hons, Stephen Roberts, PhD, Marianne Skovsager Andersen, ProfDmSci, Line Velling Magnussen, PhD, Rodolfo Hernández, PhD, Nick Oliver, ProfFRCP, Frederick Wu, ProfMD, Waljit S Dhillo, ProfPhD, Siladitya Bhattacharya, ProfMD, Miriam Brazzelli, PhD, Channa N Jayasena, PhD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:The Lancet. Healthy Longevity
Online Access:http://www.sciencedirect.com/science/article/pii/S2666756822000964